Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy

British Journal of Pharmacology

Volumn 165, Issue 1, 2012, Pages 148-166

  Yu, Y ^a   Rahmanto, Y Suryo ^a   Richardson, D R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

anti tumour chemotherapeutic; iron chelator; oral activity

Indexed keywords

2 BENZOYLPYRIDINE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; COPPER; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; IRON; IRON CHELATING AGENT; UNCLASSIFIED DRUG; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE REGULATION; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY TESTING; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INJECTIONS, INTRAVENOUS; IRON CHELATING AGENTS; LUNG NEOPLASMS; MICE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; PYRIDINES; THIOSEMICARBAZONES;

EID: 80053926659     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01526.x     Document Type: Article

References (63)

1. Abramoff MD, Magelhaes PJ, Ram SJ, (2004). Image processing with ImageJ. Biophoton Int 11: 36-42.
2. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM, (1998). Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408.
3. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, et al,. (1997). Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569-1574. (Pubitemid 27175576)
4. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, et al,. (2008). A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26: 369-379.
5. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, et al,. (2004). Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 40: 1275-1281. (Pubitemid 38526349)
6. Blatt J, (1994). Deferoxamine in children with recurrent neuroblastoma. Anticancer Res 14: 2109-2112.
7. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, et al,. (1993). Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 53: 3968-3975. (Pubitemid 23267697)
8. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al,. (1999). The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin d-dependent kinases in murine fibroblasts. EMBO J 18: 1571-1583. (Pubitemid 29127070)
9. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L, (1990). Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50: 4929-4930. (Pubitemid 20257912)
10. Donfrancesco A, Deb G, Angioni A, Maurizio C, Cozza R, Jenkner A, et al,. (1993). D-CECaT: a breakthrough for patients with neuroblastoma. Anticancer Drugs 4: 317-321. (Pubitemid 23181697)
11. Fan Y, Borowsky AD, Weiss RH, (2003). An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2: 773-782.
12. Field KM, Michael M, (2008b). Part II: liver function in oncology: towards safer chemotherapy use. Lancet Oncol 9: 1181-1190.
13. Field KM, Dow C, Michael M, (2008a). Part I: liver function in oncology: biochemistry and beyond. Lancet Oncol 9: 1092-1101.
14. Finch CA, (1982). Erythropoiesis, erythropoietin, and iron. Blood 60: 1241-1246.
15. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC, (1999). Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 39: 3-12.
16. Fu D, Richardson DR, (2007). Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110: 752-761. (Pubitemid 47105414)
17. Gao J, Richardson DR, (2001). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 98: 842-850.
18. Gharagozloo M, Khoshdel Z, Amirghofran Z, (2008). The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol 589: 1-7.
19. Hentze MW, Kuhn LC, (1996). Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 93: 8175-8182. (Pubitemid 26269529)
20. Hershko C, (1994). Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 7: 965-1000.
21. Janicke RU, Sohn D, Essmann F, Schulze-Osthoff K, (2007). The multiple battles fought by anti-apoptotic p21. Cell Cycle 6: 407-413. (Pubitemid 46393442)
22. Jansson PJ, Hawkins CL, Lovejoy DB, Richardson DR, (2010). The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study. J Inorg Biochem 104: 1224-1228.
23. Kalinowski DS, Richardson DR, (2005). The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57: 547-583. (Pubitemid 43036441)
24. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, et al,. (2007). Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 50: 3716-3729. (Pubitemid 47195478)
25. Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, et al,. (2008). A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res 32: 71-77. (Pubitemid 350100849)
26. Kingston HM, Jassie LB, (1988). Introduction to Microwave Sample Preparation-Theory and Practice. American Chemical Society Professional Reference Book: Washington D.C.
27. Lalande M, (1990). A reversible arrest point in the late G1 phase of the mammalian cell cycle. Exp Cell Res 186: 332-339.
28. Le NT, Richardson DR, (2003). Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis 24: 1045-1058. (Pubitemid 36827256)
29. Le NT, Richardson DR, (2004). Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104: 2967-2975. (Pubitemid 39434989)
30. Liu DY, Liu ZD, Hider RC, (2002). Oral iron chelators-development and application. Best Pract Res Clin Haematol 15: 369-384.
31. Lovejoy DB, Richardson DR, (2002). Novel 'hybrid' iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 100: 666-676. (Pubitemid 34761134)
32. Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, et al,. (2008). A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 26: 169-173. (Pubitemid 351357710)
33. Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, et al,. (2007). A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium. Invest New Drugs 25: 553-558.
34. Merlot AM, Pantarat N, Lovejoy DB, Kalinowski DS, Richardson DR, (2010). Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer. Mol Pharmacol 78: 675-684.
35. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, et al,. (2009). Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 84: 170-176.
36. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR, (2007). Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 109: 4045-4054. (Pubitemid 46641760)
37. Olivieri NF, Brittenham GM, (1997). Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761. (Pubitemid 27121266)
38. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al,. (1998). Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339: 417-423. (Pubitemid 28377682)
39. Rahmanto YS, Richardson DR, (2009). Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype. Biochim Biophys Acta 1793: 1210-1217.
40. Richardson DR, Baker E, (1990). The uptake of iron and transferrin by the human malignant melanoma cell. Biochim Biophys Acta 1053: 1-12. (Pubitemid 20193885)
41. Richardson DR, Milnes K, (1997). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89: 3025-3038. (Pubitemid 27172591)
42. Richardson DR, Tran EH, Ponka P, (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295-4306.
43. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, et al,. (2006). Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49: 6510-6521. (Pubitemid 44657445)
44. Sanceau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J, (2002). Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 21: 7700-7709. (Pubitemid 35398816)
45. Schrump DS, Chen A, Consoli U, (1996). Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther 3: 131-135. (Pubitemid 126732433)
46. Selig RA, White L, Gramacho C, Sterling-Levis K, Fraser IW, Naidoo D, (1998). Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res 58: 473-478. (Pubitemid 28087409)
47. Semenza GL, (1999). Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578. (Pubitemid 32250386)
48. Shen DW, Fojo A, Roninson IB, Chin JE, Soffir R, Pastan I, et al,. (1986). Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol 6: 4039-4045. (Pubitemid 17194374)
49. Sherr CJ, (1994). G1 phase progression: cycling on cue. Cell 79: 551-555. (Pubitemid 24363798)
50. Simonart T, Boelaert JR, Andrei G, van den Oord JJ, Degraef C, Hermans P, et al,. (2002). Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model. Int J Cancer 100: 140-143. (Pubitemid 34666186)
51. Sparreboom A, de Jonge MJ, Verweij J, (2002). The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer 38: 18-22. (Pubitemid 34031821)
52. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C, (1979). Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42: 547-555. (Pubitemid 9223084)
53. Suttie AW, (2006). Histopathology of the spleen. Toxicol Pathol 34: 466-503. (Pubitemid 44652214)
54. Vichinsky E, (2008). Clinical application of deferasirox: practical patient management. Am J Hematol 83: 398-402. (Pubitemid 351614754)
55. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al,. (2002). Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100: 1566-1569. (Pubitemid 34925128)
56. Weiss RH, (2003). p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4: 425-429. (Pubitemid 38050039)
57. Whitnall M, Howard J, Ponka P, Richardson DR, (2006). A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103: 14901-14906. (Pubitemid 44527826)
58. Wong CS, Kwok JC, Richardson DR, (2004). PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim Biophys Acta 1739: 70-80. (Pubitemid 39647712)
59. Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV, (2007). Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther 6: 3287-3296.
60. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D, (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704. (Pubitemid 24036020)
61. Yang DC, Jiang XP, Elliott RL, Head JF, (2001). Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Res 21: 1777-1787. (Pubitemid 32728912)
62. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, et al,. (2009). Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52: 5271-5294.
63. Yuan J, Lovejoy DB, Richardson DR, (2004). Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104: 1450-1458. (Pubitemid 39166524)